



Supplementary Figures

Supplementary Figure 1. ADA levels at baseline and three weeks after atezolizumab administration. ADA levels were compared to assess changes and the emergence of elevated responses after atezolizumab administration. ADA, antidrug antibody





Supplementary Figure 2. Response to atezolizumab treatment and survival outcomes based on ADA status. (a) Response for atezolizumab treatment according to ADA status. PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response. (b) Progression-free survival and overall survival based on ADA levels. The analysis was conducted using the median ADA value as the cutoff.


a




b



Supplementary Figure 3. Correlation between ADA and atezolizumab concentration. The analysis was conducted using the median ADA value as the cutoff.



Supplementary Figure 4. Influence of antidrug antibodies on atezolizumab efficacy according to PD-L1 expression. The analysis was conducted using the median ADA value as the cutoff.



Supplementary Table 1. Multivariate analysis of PFS and OS based on ADA levels using median as cutoff

Variables		HR (95% CI)	p-value
Progression-free survival			
Univariate analysis			
Age	<65 yr vs. ≥65 yr	0.7 (0.4-1.0)	0.077
Sex	Female vs. Male	0.9 (0.5-1.7)	0.722
Smoking	Never vs. Ever	1.4 (0.9-2.3)	0.123
PD-L1	<1% vs. ≥1%	1.0 (0.6-1.7)	0.944
Albumin	<median vs. ≥median	0.7 (0.4-1.0)	0.067
dNLR	<median vs. ≥median	1.1 (0.7-1.8)	0.592
ADA	<median vs. ≥median	2.0 (1.2-3.2)	0.004
Multivariate analysis			
Age	<65 yr vs. ≥65 yr	0.7 (0.4-1.1)	0.114
Albumin	<median vs. ≥median	0.7 (0.4-1.1)	0.092
ADA	<median vs. ≥median	1.8 (1.1-3.0)	0.018
Overall survival			
Univariate analysis			
Age	<65 yr vs. ≥65 yr	0.9 (0.5-1.6)	0.779
Sex	Female vs. Male	2.3 (0.9-5.8)	0.072
Smoking	Never vs. Ever	1.3 (0.8-2.1)	0.340
PD-L1	<1% vs. ≥1%	1.0 (0.5-1.8)	0.960
Albumin	<median vs. ≥median	0.5 (0.3-0.9)	0.013
dNLR	<median vs. ≥median	1.5 (0.9-2.4)	0.151
ADA	<median vs. ≥median	2.1 (1.2-3.5)	0.007
Multivariate analysis			
Sex	Female vs. Male	2.4 (1.0-6.0)	0.064
Albumin	<median vs. ≥median	0.5 (0.3-0.9)	0.012
ADA	<median vs. ≥median	2.2 (1.3-3.8)	0.004

dNLR, derived neutrophil-to-lymphocyte ratio